In 2003, FDA approved palonosetron as an effective drug for the control of nausea and vomiting associated to chemotherapy. Palonosetron is suggested in case of emetogenic chemotherapy schedules, in particular, in the case of cisplatin, high-dose cyclophosphamide, and anthracyclines.
, and epirubicin 90 mg/m 2 q3 wks). The antiemetic treatment consisted of 8 mg dexamethasone and 0.25 mg of palonosetron administered i.v. bolus 30 min before chemotherapy.
During the fourth cycle of chemotherapy, 1 h after the antiemetic therapy while the patient was on chemotherapy with 5-FU, she developed generalized tonic clonic seizure lasting for 8 min followed by a period of drowsiness.
Upon physical examination, blood pressure was 120/ 75 mmHg with pulse of 102 per minute regular; electrocardiogram and compute tomography scan of the head were normal. Her biochemical and hematological parameters were essentially normal. The patient was treated with diazepam 10 mg i.v. and saline infusion. Detailed investigations (neurological examination, electroencephalogram, Holter monitoring) failed to reveal anything abnormal and the patient was discharged after 2 days in good clinical conditions. We suspected palonosetron to be implicated in the occurrence of seizure and the patient received the following two cycles of chemotherapy with metoclopramide (20 mg i.v. every 8 h for 2 days) and dexamethasone without any problems. After excluding other causes and since an older selective 5-HT3 antagonist (i.e., ondansentron) has been reportedly associated with seizure [2, 3] , we suspect palonosetron to be the one responsible for the seizure.
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